BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Author(s): Wojciech Jurczak, MD, PhD¹; Michal Kwiatek, MD, PhD²; Jaroslaw Czyz, MD, PhD³; Ederson Roberto de Mattos, MD⁴; Ki-Seong Eom, MD, PhD⁵; Alexander Egle, MD⁶; Anna Panovska, MD, PhD⁷; Zhanet Grudeva Popova, MD, PhD, MHM⁸; Hsuan-Jen Shih, MD⁹; Luis Felipe Casado Montero, MD¹⁰; Paolo Sportoletti, MD¹¹; Vu Minh Hua, MBBS, PhD, FRACP, FRCPA¹²; James T. D’Olimpio, MD, FACP, FAAHPM¹³; Shinsuke Iida, MD, PhD¹⁴; Rodrigo Ito, MD¹⁵; Katherine Bao, PhD¹⁵; Anne Fink, MPH, RN¹⁵; Weiji Su, PhD¹⁵; Amy S. Ruppert, PhD¹⁵; Alejandro Levy, MD¹⁵; Tomasz Wrobel, MD, PhD¹⁶;

Source: DOI: 10.1200/JCO-25-02380

Dr. Maen Hussein's Thoughts

Pirtobrutinib demonstrated superiority over bendamustine rituximab in IRC assessed progression free survival (PFS) in treatment naïve CLL/SLL, with a 24 month PFS rate of 93.4% versus 70.7%. Overall survival trends favored pirtobrutinib, despite the study design allowing for crossover. Who would have thought this was coming????

PURPOSE

BRUIN CLL-313 is a randomized, open-label, global phase III study comparing the efficacy and safety of pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), against bendamustine plus rituximab (BendaR), a common frontline chemoimmunotherapy, in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

METHODS

Patients with previously untreated CLL/SLL without del(17p) were randomly assigned 1:1 to continuous pirtobrutinib monotherapy or BendaR, stratified by immunoglobulin heavy chain gene mutation status and Rai stage. The primary end point was independent review committee (IRC)–assessed progression-free survival (PFS); secondary end points included overall survival (OS), investigator (INV)–assessed PFS, safety, and tolerability.

RESULTS

Overall, 282 patients were randomly assigned to receive pirtobrutinib (n = 141) or BendaR (n = 141). IRC-assessed PFS was significantly improved with pirtobrutinib versus BendaR (hazard ratio [HR], 0.199 [95% CI, 0.107 to 0.367]; P < .0001), and the 24-month PFS rate was 93.4% (95% CI, 87.6 to 96.5) and 70.7% (95% CI, 61.5 to 78.1), respectively. INV-assessed PFS similarly favored pirtobrutinib (HR, 0.186 [95% CI, 0.093 to 0.371]). Interim analysis of OS favored pirtobrutinib (median follow-up 32 months; HR, 0.257 [95% CI, 0.070 to 0.934]) despite an effective crossover rate of 52.9%. In patients receiving pirtobrutinib versus BendaR: adverse event (AE)–related dose reductions occurred in 3.6% versus 31.1% of patients; grade ≥3 treatment-emergent AEs (TEAEs) occurred in 40.0% versus 67.4% of patients; and treatment discontinuations because of TEAEs occurred in 4.3% versus 15.2% of patients, respectively.

CONCLUSION

Pirtobrutinib demonstrated superiority over BendaR in IRC-assessed PFS in treatment-naïve CLL/SLL. OS trends favored pirtobrutinib despite the study design allowing for crossover. Pirtobrutinib was well tolerated, consistent with its known safety profile, and more favorable than BendaR.

Author Affiliations

¹National Research Institute of Oncology, Krakow, Poland; ²AIDPORT Clinical Trials Hospital, Skorzewo, Poland; ³Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland; ⁴Hematology Department, Hospital Amaral Carvalho, Jau, Brazil; ⁵Catholic Hematology Hospital, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea; ⁶Third Medical Department for Hematology, Oncology, Hemostaseology, Infectious Disease and Rheumatology, Paracelsus University Hospital, Salzburg, Austria; ⁷Department of Internal Medicine, Hematology and Oncology, Masaryk University, Brno, Czech Republic; ⁸Department of Clinical Oncology, Medical University of Plovdiv, Plovdiv, Bulgaria; ⁹Division of Hematology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan R.O.C; ¹⁰HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Instituto de Investigación Sanitaria HM Hospitales, Madrid, Spain; ¹¹Department of Medicine and Surgery, Institute of Hematology Centro di Ricerca Emato-Oncologica (CREO), University of Perugia, Perugia, Italy; ¹²Liverpool Hospital, Liverpool, NSW, Australia; ¹³Clinical Research Alliance, Westbury, NY; ¹⁴Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; ¹⁵Eli Lilly and Company, Indianapolis, IN; ¹⁶Wroclaw Medical University, Wrocław, Poland

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

Median progression-free survival (PFS) was significantly longer with mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) than with R-GemOx (11.5 months vs 3.8 months). The overall response rate (ORR) was significantly higher with Mosun-Pola compared with R-GemOx (70% vs 40%; P < .0001), with complete response rates of 51% and 24%, respectively. Cytokine release syndrome (CRS) occurred in fewer than 5% of patients.

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial Open Access

Acalabrutinib in patients aged ≥80 years demonstrated 12-month progression-free (PFS) and overall survival (OS) rates of 93.3% and 95.7%, respectively, after a median follow-up of 19 months. Adverse events were severe but rarely included major bleeding or atrial fibrillation. Patient-reported quality of life improved, including amerlioration of frailty.

Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma

The EPCORE NHL-2 phase 1b/2 trial evaluated fixed-duration epcoritamab plus R2 in R/R FL after at least one prior line, showing impressive efficacy with an overall response rate (ORR) of 96% and a complete response (CR) of 88%, and 2-year rates for remaining in CR (82%), progression-free survival (PFS) (76%), overall survival (OS) (90%), and freedom from next therapy (84%)—all with non-reached medians. High-risk groups did just as well, with CR rates of 90% in primary refractory, 82% in double refractory. MRD negativity was achieved by 86% overall. Safety was manageable, with mostly low-grade CRS (grade 1/2/3: 38%/11%/2%), neutropenia (65%), and COVID-19 (59%)—notably, no CRS-related discontinuations. This chemo-free, off-the-shelf regimen is delivering deep, durable remissions with practical outpatient dosing—something we’ve all been hoping to see for R/R FL.

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML

Ziftomenib 600 mg daily achieved a CR/CRh rate of 22% (61% MRD-negative among responders) and an overall response rate (ORR) of 33% in heavily pretreated R/R NPM1-mutated AML, with a median duration of response (DOR) of 4.6 months and median overall survival (OS) of 6.6 months (18.4 months in responders). Efficacy was consistent across subgroups, including prior venetoclax and FLT3/IDH co-mutations, and safety was manageable with on-target differentiation syndrome in 25% (15% grade 3; no grade 4–5), low myelosuppression, rare QTc prolongation (3%), and only 3% discontinuations for drug-related AEs. This non-cytotoxic, oral menin inhibitor offers meaningful activity in a high-risk population and is a practical option while we await combination data.

A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma Available to Purchase

The phase 2 trial of Moga-CHOP (CHOP + mogamulizumab) in older patients with aggressive adult T-cell leukemia/lymphoma (ATL) demonstrated a significant improvement in 1-year PFS (36.2% vs 16% historical control), with a 1-year OS of 66.0% and a CR rate of 64.6%. The overall response rate (ORR) was high at 91.7%, and the median overall survival (OS) reached 1.6 years. Notably, CCR4 mutations and Moga-associated cutaneous AEs correlated with better OS, and the regimen was generally tolerable with no unexpected toxicities. Bottom line: Moga-CHOP is now a strong first-line option for older, transplant-ineligible ATL patients, and it’s encouraging to see these survival gains in a population with historically poor outcomes.